Altamira Therapeutics Ltd. (CYTOF)
OID · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland, Australia, the United States, and Europe. The company develops and supplies peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues through xPhore platform; and offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens It is also developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; and AM-125 that is in post phase II clinical trial for the intranasal treatment of vertigo. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.
Peers in Healthcare
Altamira Therapeutics Ltd. has no peer companies in this window.
Recent press releases
Altamira Therapeutics Ltd. has not issued a press release in this window.
SEC filings
All filings →Altamira Therapeutics Ltd. has not filed an SEC document in this window.
Insider trades
All insider trades →Altamira Therapeutics Ltd. has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at Altamira Therapeutics Ltd.
All people →No officers or directors have been indexed for Altamira Therapeutics Ltd..